Treatment News : Best HIV Treatment Practices Among Women Receiving ADAP

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » February 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

February 16, 2011

Best HIV Treatment Practices Among Women Receiving ADAP

Women enrolled in AIDS Drug Assistance Programs (ADAPs) in California, New York and Illinois were more likely to be taking antiretroviral (ARV) medication according to treatment guidelines than women not on ADAPs. These findings, published in the March 1 issue of the Journal of Acquired Immune Deficiency Syndromes, hold up even when the analysis includes women with public or private health insurance.

Researchers have learned a great deal about the factors that increase or decrease a person’s chances of receiving ARV therapy, in accordance with recommendations spelled out national HIV treatment guidelines. People with histories of drug and alcohol abuse are generally less likely to be on treatment when they ought to be. The same is true of African Americans, people with lower incomes and people living in certain geographic regions in the United States. What remains unexplored, however, is how access to free or discounted medications through ADAPs affect whether a person is being treated according to the guidelines.

This question has particular relevance, because the ADAP programs—which provide medications to more than 180,000 people in total—are reaching a financial crisis point. A number of states have instituted waiting lists for new enrollees, and others have made their enrollment qualifications so strict that people already in ADAP programs are being kicked off. Thus, understanding the additional value that ADAP programs provide is essential.

To help answer these important questions, Thomas Yi, PharmD, from the University of California at San Francisco, and his colleagues analyzed data from the Women’s Interagency HIV Study (WIHS), which is following more than 2,000 HIV-positive and HIV-negative women in three states and the District of Columbia.

Yi’s team looked at 1,139 HIV-positive women enrolled in the WIHS study during 2008 from California, New York and Illinois. In all, most of the women were older than 40 and most categorized their race as black. About two thirds reported being unemployed, and 50 percent earned less than $12,000 per year. Half had health insurance through Medicaid, 33 percent had either private insurance or Medicare, and the remaining 17 percent had no insurance. In all, 24 percent were enrolled in ADAPs.

Yi and his colleagues considered women to be on highly active antiretroviral treatment (HAART) if they were taking guidelines approved medications and had started treatment at the CD4 counts recommended in the guidelines published at that time, in 2008. In all, 74 percent of the participants with CD4 counts under 350 were taking guidelines approved ARVs, 2 percent were taking ARVs not recommended by guidelines, and 24 percent should have been on ARVs but were not.

After accounting for a number of factors that traditionally predict delayed use of ARVs—such as race, income and substance use history—Yi’s team found that women on ADAP programs were two times more likely to be taking ARV therapy in accordance with treatment guidelines than women not on ADAP programs. This was true even when the team looked whether women had private health insurance. Consistent with previous findings, black women, women with incomes less than $12,000 per year and women with heavier alcohol consumption were all less likely to be on treatment in accordance with guidelines.

To determine whether use of other important medications would also increase in ADAP recipients, Yi and his colleagues also looked at the use of medications for high blood pressure. The team did find that women who needed to be taking high blood pressure medication were more likely to do so if they were enrolled in ADAP than women not enrolled in ADAP, but the difference was small enough that it could have occurred by chance.

“In summary, in light of recent and proposed funding cuts for ADAP and projected increase in demand of ADAP services, we provided evidence that this program was strongly associated with better HAART medication use,” the authors state.

“We also found that populations that constitute the majority of ADAP enrollees, those with lower income and of black descent, had decreased HAART use compared with those with higher incomes and of nonblack descent. As a result, state ADAPs should be continued to improve antiretroviral use in these at-risk populations,” they concluded.

Search: HIV, treatment, antiretroviral therapy, ADAP, AIDS Drug Assistance Program, WIHS


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    chipper52
    Palm Springs
    California


    Sloan1
    Dallas
    Texas


    Heartland4now
    Tacoma
    Washington


    kmfdm221
    Arcata
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.